Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Angiogenesis Inhibitors × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

pembrolizumab 91 Carboplatin 53 Cyclophosphamide 49 Nivolumab 44 Specimen Handling 41 Magnetic Resonance Spectroscopy 38 Biopsy 38 fludarabine 36 Bevacizumab 35 Dexamethasone 34 Gemcitabine 33 venetoclax 30 Paclitaxel 30 Temozolomide 29 Cisplatin 28 atezolizumab 26 Injections 23 Irinotecan 22 Rituximab 21 Pemetrexed 21 Docetaxel 19 Radiotherapy 18 Prednisone 18 Lenalidomide 17 Fluorouracil 17 Cetuximab 17 Azacitidine 17 durvalumab 16 abemaciclib 15 Oxaliplatin 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06840119 2026-01-28

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Immunocore Ltd

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡